By Josh BeckermanGilead Sciences Inc.'s remdesivir, commonly used to treat hospitalized Covid-19 patients, has received Food and Drug Administration approval for some non-hospitalized patients. Gilead said the expanded indication allows the drug to be administered in qualified outpatient settings that can provide daily intravenous infusions over three consecutive days.

Source: Wall Street Journal January 22, 2022 18:59 UTC